Search Results

Terumo Cardiovascular, a global leader in cardiovascular surgery technologies, announced that the U.S. Food and Drug Administration has granted 510 clearance for the CDI OneView Monitoring System.

Terumo Blood and Cell Technologies (Terumo BCT) announces U.S. Food and Drug Administration (FDA) clearance of the Reveos Automated Whole Blood Processing System, the first whole blood automation device available in the U.S. that processes whole blood into platelets and other components in a single centrifugation cycle.

Terumo Medical Corporation is pleased to announce the launch of its new AZUR HydroPack Peripheral Coil System in the United States.

Terumo Blood and Cell Technologies, a medical technology company, recently received U.S. Food and Drug Administration 510 clearance for the Rika Plasma Donation System™ with the iNomi™ Nomogram.

NAMSA, a world-leading MedTech Contract Research Organization offering global end-to-end development services, and Terumo Aortic, a developer of aorta-focused medical devices, announced that they have entered into a strategic outsourcing partnership to assist with the acceleration and commercialization of Terumo Aortic’s innovative aortic disease products.

LaVista, Nebraska – Streck is pleased to announce the launch of Protein Plus BCTTM, a direct draw whole blood collection tube intended for the stabilization of draw-time concentrations of plasma proteins during ambient temperature storage. Protein Plus BCT is For Research Use Only. Not for use in diagnostic procedures.

Today, the U.S. Food and Drug Administration (FDA) cleared the new plasma collection system developed by Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company.

Gencurix, a leading provider of cancer molecular diagnostics, announced the release of clinical research results directly comparing the accuracy of its breast cancer prognostic test, GenesWell BCT, with Oncotype DX, the globally top-selling test, confirming its outstanding performance.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) announces a clinical supply agreement with BeiGene, Ltd. (NASDAQ: BGNE) (“BeiGene”) to evaluate the safety and efficacy of Bria-OTS™, BriaCell’s next generation immunotherapy, in combination with BeiGene’s anti-PD-1 antibody, tislelizumab, for the treatment of advanced heavily pretreated metastatic breast cancer.

Terumo Blood and Cell Technologies announces U.S. FDA clearance and official launch of its IMUGARD® WB Platelet Pooling Set, which supports extended shelf life of whole blood-derived platelets from five days to seven days..